Defy Medical review

Defy may suit someone seeking hormone and peptide care through one clinic. Confirm the proposed medication, monitoring and full cost before enrolling; a consultation-and-lab model does not establish that a peptide improves long-term health.

Defy Medical offers hormone-and-wellness care through telemedicine. Its previously published peptide catalog included compounded treatments and some branded growth-hormone products, but the current menu and formulations need confirmation with the clinic.

The peptide page describes a lab- and symptom-based assessment, follow-up and patient-portal access, with no subscriptions or contracts advertised. Terms effective April 2, 2026 limit services to adults 18 or older in authorized jurisdictions. Confirm the clinician, required tests and monitoring schedule; educational mentions of a peptide do not establish that it can be prescribed or dispensed.

Sales are generally final, and a consultation is not refundable solely because no prescription results. Billing errors may result in nonexpiring account credit; refunds of credit are discretionary and may have a minimum-balance requirement.

Lab-order validity differs between official pages: the April terms allow 12 months plus a free 12-month renewal on request, while Clinical Procedures lists three months plus a free three-month renewal. Refund conditions are separate from order validity. Both pages limit lab refunds to before specimen submission. The terms describe account credit minus $25, with an original-method refund possible if requirements are met; Clinical Procedures describes original-method refunds within 90 days and account credit minus $25 at 91–180 days. The terms also disclaim refund or credit after the order and any renewal expire. Ask which validity period and refund process apply to your order before paying.

Obtain an itemized quote for consultation, testing, medication and repeat monitoring. Current peptide prices and the complete starting total remain unconfirmed; an older hormone-treatment average is not a peptide price.

Defy does not accept insurance or guarantee reimbursement. The April 2026 terms offer a detailed superbill on request but say Defy will not otherwise assist with claims. The active Clinical Procedures page instead offers assistance completing a CMS-1500 claim form. Confirm what paperwork is available and which refund conditions apply before paying.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. The previously published peptide menu primarily described compounded preparations, which are not FDA-approved and are not therapeutically equivalent to approved branded drugs. Earlier growth-hormone listings also named branded somatropin products with narrow approved uses. Current catalog access and orderability remain unconfirmed; ask which exact formulation and manufacturer would be prescribed. The evidence is uneven across the list and worth separating: sermorelin and ipamorelin act on the growth-hormone axis, which is a genuine mechanism, but long-term outcome data is thin. Tesamorelin is a partial exception — an FDA-approved version exists for HIV-associated lipodystrophy, a narrow indication that is not the same thing as a general anti-aging use. BPC-157, TB-500, GHK-Cu, AOD-9604, KPV, epithalon and MOTS-c have essentially no controlled human outcome trials behind them. FDA lists several of these substances under nominations withdrawn by their nominators and continues to describe safety concerns. That classification is not approval of a finished product or a determination that every proposed preparation can be compounded. Confirm what can actually be dispensed to you today rather than assuming the published menu is settled. Individual results vary.